These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23958550)

  • 1. AngioMap is a novel image analysis algorithm for assessment of plasma cell distribution within bone marrow vascular niche.
    Salama ME; Lange H; Tripp SR; Kohan J; Landis ND; Krueger JS; Potts SJ
    Appl Immunohistochem Mol Morphol; 2014 Aug; 22(7):550-4. PubMed ID: 23958550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
    Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
    Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma.
    Babarović E; Valković T; Štifter S; Budisavljević I; Seili-Bekafigo I; Duletić-Načinović A; Lučin K; Jonjić N
    Am J Clin Pathol; 2012 Jun; 137(6):870-8. PubMed ID: 22586045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
    Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
    Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial distribution of blood vessels and CD34+ hematopoietic stem and progenitor cells within the marrow cavities of human cancellous bone.
    Watchman CJ; Bourke VA; Lyon JR; Knowlton AE; Butler SL; Grier DD; Wingard JR; Braylan RC; Bolch WE
    J Nucl Med; 2007 Apr; 48(4):645-54. PubMed ID: 17401104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
    Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
    Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
    Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
    Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring.
    Liu ZY; Tian MY; Deng L; Wang YS; Xing R; Liu H; Fu R
    Hematol Oncol; 2019 Oct; 37(4):401-408. PubMed ID: 31291481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
    Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
    Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
    Ribas C; Colleoni GW; Silva MR; Carregoza MJ; Bordin JO
    Eur J Haematol; 2004 Nov; 73(5):311-7. PubMed ID: 15458509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cell quantification in bone marrow by computer-assisted image analysis.
    Went P; Mayer S; Oberholzer M; Dirnhofer S
    Histol Histopathol; 2006 Sep; 21(9):951-6. PubMed ID: 16763944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
    Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M
    Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094
    [No Abstract]   [Full Text] [Related]  

  • 16. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
    Ren Z; Spaargaren M; Pals ST
    Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of in vitro growth of multiple myeloma cells.
    Zlei M; Egert S; Wider D; Ihorst G; Wäsch R; Engelhardt M
    Exp Hematol; 2007 Oct; 35(10):1550-61. PubMed ID: 17889722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of bone marrow angiogenesis in multiple myeloma.
    Rajkumar SV; Leong T; Roche PC; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR
    Clin Cancer Res; 2000 Aug; 6(8):3111-6. PubMed ID: 10955791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.